Pliant Therapeutics Inc
NASDAQ:PLRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of
Pliant Therapeutics Inc (PLRX) under the Base Case is 2.6534 USD per share.
Compared with the current market price of 0.6932 USD, the stock appears
Undervalued by 74% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Pliant Therapeutics Does
Pliant Therapeutics is a biotechnology company that develops drug candidates for fibrotic diseases, where the body makes too much scar tissue in organs such as the lungs. Its main focus has been on medicines that block integrins, proteins that help drive the scarring process. The company is still in the drug-development stage, so it does not sell a commercial medicine yet.
- Headquarters
- United States of America US
- Employees
- 49
- IPO date
- Jun 3, 2020
Continue PLRX Research
Decided on Pliant Therapeutics? Get an email when PLRX reaches the price you’d buy at. Free with an account.
Other Pliant Therapeutics listings
What is the Intrinsic Value of one PLRX stock?
The intrinsic value for
Pliant Therapeutics Inc (PLRX) under the Base Case is 2.6534 USD.
Is PLRX stock undervalued or overvalued?
Compared with the current market price of 0.6932 USD, the stock appears Undervalued by 74% .